Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit.

Abstract:

BACKGROUND:The optimal therapeutic strategy for metastatic colorectal cancer patients is still a matter of debate. There are no prognostic variables indicating how many lines individual patients ought to receive, and whether later lines could be effective even when earlier ones were not. PATIENTS AND METHODS:We retrospectively collected data from 420 consecutive patients with metastatic colorectal cancer at our institution, describing the proportion of patients who received second or later lines of therapy and the chance of a line of treatment being active when the previous line was not. For each line of treatment, we defined clinical benefit as the probability of not having had evidence of disease progression 6 months after the start of chemotherapy. RESULTS:Of the 373 patients with disease progression after first-line chemotherapy (1L), 277 received a second line (2L) (probability of being submitted to a 2L (P(2L)) = 74.3%): 143 (63.3%) of 226 received a 3L (P(3L)), and 56 (45.9%) of 122 were submitted to a 4L (P(4L)). Joint probabilities were: 2L 74.3%, 3L 47.0%, and 4L 21.6%. A total of 298 (71.5%) of 417 patients had a clinical benefit with 1L; 134 (48.6%) of 276 with 2L; 50 (35.2%) of 142 with 3L; and 12 (25.0%) of 48 with 4L. Taking all these data together, 31% of the patients who experienced early progression at 1L had the chance to have a clinical benefit with any further lines. CONCLUSION:Our study demonstrated that of 4 patients submitted to a 1L, about 3 will receive a 2L, about 2 a 3L, and nearly 1 a 4L. Later lines could be beneficial even though earlier ones were not.

journal_name

Clin Colorectal Cancer

authors

Tampellini M,Di Maio M,Baratelli C,Anania L,Brizzi MP,Sonetto C,La Salvia A,Scagliotti GV

doi

10.1016/j.clcc.2017.03.019

subject

Has Abstract

pub_date

2017-12-01 00:00:00

pages

372-376

issue

4

eissn

1533-0028

issn

1938-0674

pii

S1533-0028(16)30208-0

journal_volume

16

pub_type

杂志文章
  • Interval colorectal cancer after colonoscopy.

    abstract:BACKGROUND:As more patients are screened for colorectal cancer a small but significant number of interval cancers develop after colonoscopy for colorectal cancer screening. MATERIALS AND METHODS:We reviewed records of 75,314 adult patients who underwent colonoscopy for screening or diagnostic purposes between 1998 and...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2014.11.001

    authors: Richter JM,Campbell EJ,Chung DC

    更新日期:2015-03-01 00:00:00

  • Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.

    abstract::Replacing infusional 5-fluorouracil (5-FU) leucovorin (LV) with oral capecitabine would be more convenient to patients, because it would lead to reduced hospital chair time and infusion-related toxicities. Previous trials with oral capecitabine-based regimens (other than XELOX [capecitabine/oxaliplatin]) have failed t...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2006.n.044

    authors: Tyagi P,Grothey A

    更新日期:2006-11-01 00:00:00

  • Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.

    abstract:INTRODUCTION:Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU. Given the additional benefit of oxaliplatin over FP alone in the management of color...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.09.006

    authors: Chakrabarti S,Sara J,Lobo R,Eiring R,Finnes H,Mitchell J,Hartgers M,Okano A,Halfdanarson T,Grothey A

    更新日期:2019-03-01 00:00:00

  • First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.

    abstract:BACKGROUND:Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC. PATIENTS AND METHODS:Using a modified Simon accelerated titration design, adults with...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2020.08.003

    authors: Winer A,Denlinger CS,Vijayvergia N,Cohen SJ,Astaturov I,Dotan E,Gallant JN,Wang EW,Kunkel M,Lim B,Harvey HA,Sivik J,Korzekwa K,Ruth K,White K,Cooper HS,Ross EA,Zhou L,El-Deiry WS

    更新日期:2020-08-19 00:00:00

  • Local excision for rectal carcinoma.

    abstract::Local excision is an alternative approach to radical proctectomy for rectal cancer, but from an oncologic standpoint, it is a compromise, and its role remains controversial. Careful patient selection is essential because local excision is generally considered only for early rectal cancer with no evidence of nodal meta...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2008.n.050

    authors: Kim E,Hwang JM,Garcia-Aguilar J

    更新日期:2008-11-01 00:00:00

  • Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.

    abstract::Bevacizumab is a humanized monoclonal antibody approved by the US Food and Drug Administration for use in combination with fluorouracil (FU)-based chemotherapy for first-line treatment of patients with metastatic colorectal carcinoma (CRC). Its mechanism of action is inhibition of tumor angiogenesis by neutralizing va...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2010.n.008

    authors: Gamboa EO,Rehmus EH,Haller N

    更新日期:2010-01-01 00:00:00

  • Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.

    abstract::To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current trea...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clcc.2015.10.002

    authors: Goldstein DA,Zeichner SB,Bartnik CM,Neustadter E,Flowers CR

    更新日期:2016-03-01 00:00:00

  • Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer.

    abstract::Epidermal growth factor receptor (EGFR) has been validated as an important target in the treatment of metastatic colorectal cancer (mCRC). While initial studies focused on the treatment of disease that was refractory to available chemotherapy agents, 2 recent themes have emerged: the use of KRAS mutation status to sel...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2010.s.006

    authors: Stein S,Cohen DJ,Hochster HS

    更新日期:2010-06-01 00:00:00

  • Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions.

    abstract::The use of adjuvant chemotherapy has improved survival in early-stage colon cancer. Ongoing adjuvant clinical trials are evaluating the addition of targeted therapies to standard chemotherapy regimen. Preliminary results with bevacizumab were disappointing. Also, cetuximab added to chemotherapy does not seem to be bet...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2010.n.039

    authors: Chibaudel B,Tournigand C,André T,Larsen AK,de Gramont A

    更新日期:2010-12-01 00:00:00

  • Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.

    abstract::The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has ushered in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). The anti-EGFR monoclonal antibodies cetuximab and panitu...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clcc.2015.05.006

    authors: Lee MS,Kopetz S

    更新日期:2015-12-01 00:00:00

  • Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry.

    abstract:BACKGROUND:Colorectal cancer (CRC) is a common malignancy. There is growing evidence that CRC incidence is increasing in the younger population. There is controversy surrounding the prognosis of young patients with CRC. In this study we reviewed Australian patients with metastatic CRC (mCRC) who were younger than 40 ye...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2015.07.005

    authors: Vatandoust S,Price TJ,Ullah S,Roy AC,Beeke C,Young JP,Townsend A,Padbury R,Roder D,Karapetis CS

    更新日期:2016-03-01 00:00:00

  • Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.

    abstract:BACKGROUND:We performed a meta-analysis of previous reports evaluating the effect of mFIO (modified FOLFIRINOX; leucovorin, 5-fluorouracil, irinotecan, oxaliplatin) regimens in advanced pancreatic cancer. MATERIALS AND METHODS:We performed a meta-analysis of reported studies in PubMed, Scopus, and Web of Science (1950...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clcc.2018.03.007

    authors: Usón Junior PLS,Rother ET,Maluf FC,Bugano DDG

    更新日期:2018-09-01 00:00:00

  • Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.

    abstract:BACKGROUND:Köhne prognostic score is used to classify patients with metastatic colorectal cancer (mCRC) as high, intermediate, or low risk. Using data from 2 phase III trials, we analyzed survival in patients categorized according to Köhne prognostic category and virus-induced rapidly accelerated fibrosarcoma murine sa...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2017.09.006

    authors: Siena S,Rivera F,Taieb J,Peeters M,Prenen H,Koukakis R,Demonty G,Köhne CH

    更新日期:2018-03-01 00:00:00

  • Thymidylate synthase: a critical target for cancer chemotherapy.

    abstract::Thymidylate synthase (TS) is a key enzyme in the synthesis of 2'-deoxythymidine-5'-monophosphate, an essential precursor for DNA biosynthesis. For this reason, this enzyme is a critical target in cancer chemotherapy. As the first TS inhibitor in clinical use, 5-fluorouracil (5-FU) remains widely used for the treatment...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2002.n.003

    authors: Rose MG,Farrell MP,Schmitz JC

    更新日期:2002-02-01 00:00:00

  • Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.

    abstract::Modern chemotherapy combinations for metastatic colorectal cancer (mCRC) comprise infusional 5-fluorouracil (5-FU), leucovorin, and irinotecan or oxaliplatin. The fluoropyrimidine derivative capecitabine is at least as effective as 5-FU plus leucovorin bolus regimens. It displays a favorable toxicity profile and offer...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2008.n.015

    authors: Moosmann N,Heinemann V

    更新日期:2008-03-01 00:00:00

  • Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid.

    abstract:BACKGROUND:5-Fluorouracil (5-FU) chemotherapy is associated with severe and unpredictable toxicity in a significant proportion of patients. 5,10-Methylenetetrahydrofolate and 5-fluorodeoxyuridine monophosphate bind to thymidylate synthase and together inhibit its function, resulting in cytotoxicity. We hypothesized tha...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2016.06.001

    authors: Yan M,Ho C,Winquist E,Jonker D,Rayson D,Stitt L,Tokmakejian S,Tomiak A,Vincent MD

    更新日期:2016-12-01 00:00:00

  • Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases.

    abstract::The development of brain metastases originating from colorectal cancer (CRC) is an infrequent phenomenon occurring in < 5% of patients. Yet, it is feasible that physicians will be diagnosing more patients with brain metastases because of the prolonged survival in our current patient population. The anti-angiogenic age...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2008.n.010

    authors: Bhaskara A,Eng C

    更新日期:2008-01-01 00:00:00

  • A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.

    abstract:INTRODUCTION:The aim of this study was to evaluate the efficacy and safety of maintenance therapy with axitinib versus placebo following induction therapy in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In this double-blinded, phase II trial, patients with mCRC who had not progressed after 6...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clcc.2018.02.004

    authors: Grávalos C,Carrato A,Tobeña M,Rodriguez-Garrote M,Soler G,Vieitez JM,Robles L,Valladares-Ayerbes M,Polo E,Limón ML,Safont MJ,Martínez de Castro E,García-Alfonso P,Aranda E,Spanish Cooperative Group for the Treatment of Digest

    更新日期:2018-06-01 00:00:00

  • Patients with colorectal and renal cell carcinoma diagnoses appear to be at risk for additional malignancies.

    abstract:UNLABELLED:Patients with colorectal cancer (CRC) and renal cell carcinoma (RCC) may be at risk for additional primary malignancies. A review of 101 patients with these concurrent diagnoses was performed. Forty-two percent of patients had 1 or more additional malignancies; none appeared to be associated with Lynch syndr...

    journal_title:Clinical colorectal cancer

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.clcc.2012.07.004

    authors: Steinhagen E,Moore HG,Lee-Kong SA,Shia J,Eaton A,Markowitz AJ,Russo P,Guillem JG

    更新日期:2013-03-01 00:00:00

  • A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.

    abstract:PURPOSE:Capecitabine has shown similar efficacy to 5-fluorouracil (5-FU); a regimen containing 2 weeks of capecitabine/oxaliplatin (CapOx) has demonstrated noninferiority to infusional 5-FU/oxaliplatin/leucovorin (FOLFOX) for the treatment of metastatic colorectal cancer (mCRC). This phase II study explores the efficac...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2010.n.021

    authors: Lubner SJ,Loconte NK,Holen KD,Schelman W,Thomas JP,Jumonville A,Eickhoff JC,Seo S,Mulkerin DL

    更新日期:2010-07-01 00:00:00

  • Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.

    abstract:BACKGROUND:In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer. PATIENTS AND METHODS...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2006.n.037

    authors: Wolpin BM,Clark JW,Meyerhardt JA,Earle CC,Ryan DP,Enzinger PC,Zhu AX,Blaszkowsky L,Battu S,Fuchs CS

    更新日期:2006-09-01 00:00:00

  • Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.

    abstract:BACKGROUND:Gemcitabine-related pneumonitis (GRP) has been reported relatively frequently for pancreas cancer in the literature; however, underlying risk factors and optimal management remain to be defined. We studied a cohort of patients with GRP and investigated potential predisposing factors in pancreatic cancer pati...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2015.08.003

    authors: Sahin IH,Geyer AI,Kelly DW,O'Reilly EM

    更新日期:2016-03-01 00:00:00

  • Targeted therapy in colorectal cancer.

    abstract::Adjuvant therapy can reduce the risk of disease recurrence in patients with stage II-IV colorectal cancer. Recently, 3 monoclonal antibodies have been shown to improve clinical outcome in this group of patients. Bevacizumab is an antiangiogenesis agent that has been shown in clinical and preclinical models to reverse ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2007.n.004

    authors: Wadler S

    更新日期:2007-01-01 00:00:00

  • Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.

    abstract:BACKGROUND:Individually, oxaliplatin and irinotecan have substantial activity in metastatic colorectal cancer (CRC) in combination with 5-fluorouracil/leucovorin. A combination regimen using all 4 agents could potentially increase response rates in CRC. PATIENTS AND METHODS:A multicenter phase II trial of oxaliplatin ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CCC.2007.n.017

    authors: McWilliams RR,Goetz MP,Morlan BW,Salim M,Rowland KM,Krook JE,Ames MM,Erlichman C

    更新日期:2007-05-01 00:00:00

  • Functional imaging of colorectal cancer: positron emission tomography, magnetic resonance imaging, and computed tomography.

    abstract::In the past 10 years, overall survival and disease-free survival of patients with colorectal cancer (CRC) has improved substantially because of a combination of factors: (1) more accurate staging as a result of advances in imaging technology; (2) refinements in surgical technique; (3) 'curative' metastasectomy for pat...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2009.n.013

    authors: Kapse N,Goh V

    更新日期:2009-03-01 00:00:00

  • Intussusception in colorectal cancer.

    abstract::Adult intussusception is a rare occurrence and, unlike in childhood, is usually associated with an underlying tumor. Although computed tomography (CT) imaging can identify an intussusception and point toward a cause, diagnosis is challenging if it is only intermittent. When an intussusception presents in the context o...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2008.n.028

    authors: Chand M,Bradford L,Nash GF

    更新日期:2008-05-01 00:00:00

  • Pattern of use of adjuvant chemotherapy for stage II colon cancer: a single-institution experience.

    abstract:PURPOSE:American Society of Clinical Oncology (ASCO) guidelines define high-risk prognostic features (HRFs) in stage II colon cancer and recommend limiting adjuvant chemotherapy to patients with HRFs. We evaluated the extent to which HRFs influenced decisions on adjuvant chemotherapy before and after publication of the...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:

    authors: Osarogiagbon RU,Sachdev JC,Khattak AG,Kronish LE

    更新日期:2009-04-01 00:00:00

  • Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age.

    abstract:BACKGROUND:Screening protocols for colorectal cancer are broadly recommended and effective in reducing mortality. However, populations from different age groups can harbor distinct pathologic and molecular profiles that can also be influenced by screening and polyp resection, especially in older ages. PATIENTS AND MET...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2020.06.004

    authors: Pereira AAL,Fernandes GDS,Braga GTP,Marchetti KR,Mascarenhas CDC,Gumz B,Crosara M,Dib L,Girardi D,Barrichello A,Seidler H

    更新日期:2020-12-01 00:00:00

  • Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.

    abstract::This article reviews the current status of the topoisomerase I (top I) inhibitors in the treatment of gastrointestinal (GI) malignancies. We focus on oral drug administration, the mode of administration that is generally preferred by patients with cancer. However, the great majority of the studies have been performed ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/ccc.2004.n.017

    authors: Kuppens IE,Beijnen J,Schellens JH

    更新日期:2004-09-01 00:00:00

  • Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.

    abstract:INTRODUCTION:Bevacizumab improves outcome for patients with advanced colorectal cancer (CRC) when added to chemotherapy. The HORIZON I trial resulted in similar outcome with bevacizumab or cediranib, a small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor, as treatment of advanc...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clcc.2013.11.002

    authors: Bar J,Spencer S,Morgan S,Brooks L,Cunningham D,Robertson J,Jürgensmeier JM,Goss GD

    更新日期:2014-03-01 00:00:00